Compare Ishares Msci Italy ETF (EWI) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Gilead Sciences, Inc. — how do they compare? Ishares Msci Italy ETF trades at $55.99 (market cap $1.14B), while Gilead Sciences, Inc. trades at $146.25 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 160× Ishares Msci Italy ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Ishares Msci Italy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 52 Days and Gilead Sciences, Inc. for 111 Days on average.
| EWI | GILD | |
|---|---|---|
Market Cap | $1.14B | $182.40B |
Volume | 2,377,947 | 4,469,821 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $155.80 |
52-Week Low | $50.31 | $116.74 |
Typical Hold Time | 52 Days | 111 Days |
Enterprise Value | — | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI, the iShares MSCI Italy ETF, trades at $56.35, down 2.74% on the day, reflecting a bearish technical outlook with all moving averages signaling sell. The ETF provides exposure to Italian financials, utilities, and industrials, benefiting from EU recovery investments and sector consolidation. Recent news highlights ECB rate hikes and eurozone economic concerns, with energy-driven inflation posing headwinds.
The outlook remains cautious due to macroeconomic pressures from rising interest rates and inflation, though structural investments in Italian infrastructure offer long-term potential. Key risks include eurozone volatility and energy price shocks, while technical indicators suggest near-term weakness. Investors should weigh sector-specific strengths against broader market sentiment.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
